<DOC>
	<DOCNO>NCT02230566</DOCNO>
	<brief_summary>The Phase 3 study use novel randomize , intra-subject placebo-controlled , single crossover design , refer Blind Start , evaluate safety efficacy UX003 .</brief_summary>
	<brief_title>A Phase 3 Study UX003 rhGUS Enzyme Replacement Therapy Patients With MPS 7</brief_title>
	<detailed_description>The Blind Start novel design whereby subject randomize one 4 group , represent different treatment sequence , cross UX003 different pre-defined time point blind manner . All group receive minimum 24 week treatment 4 mg/kg UX003 every week .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VII</mesh_term>
	<criteria>Confirmed diagnosis MPS 7 base leukocyte fibroblast glucuronidase enzyme assay genetic testing Elevated uGAG excretion minimum 3fold mean normal age ( Screening ) Apparent clinical sign lysosomal storage disease judge Investigator , include least one following : enlarge liver spleen , joint limitation , airway obstruction pulmonary problem , limitation mobility still ambulatory Aged 5 35 year , inclusive Willing able provide write informed consent , case subject age 18 ( 16 year , depend region ) , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Sexually active subject must willing use acceptable highly effective method contraception participate study 30 day follow last dose . Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include experience menarche , tubal ligation least one year prior Screening , total hysterectomy . Na√Øve treatment UX003 Undergone successful bone marrow stem cell transplant degree detectable chimaerism donor cell Major surgery within 3 month prior study entry plan major surgery study may allow safe participation study Presence history hypersensitivity rhGUS excipients , judgment Investigator , place subject increase risk adverse effect . Pregnant breastfeed Screening plan become pregnant ( self partner ) time study Use investigational product ( drug device combination ) within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment . Presence condition severity acuity , opinion Investigator , warrant immediate surgical intervention treatment may allow safe participation study . Concurrent disease condition , laboratory abnormality , view Investigator , place subject high risk poor treatment compliance complete study , would interfere study participation introduce additional safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MPS 7</keyword>
	<keyword>Sly Syndrome</keyword>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>MPS VII</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Mucopolysaccharidosis type 7</keyword>
	<keyword>rare disease</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>metabolic disorder</keyword>
</DOC>